What the Tirzepatide Calculator does

A vial of lyophilised tirzepatide is labelled in milligrams. A syringe is not: it is graduated in millilitres, or in the unit markings printed along its barrel. Nothing on either object tells you how the two relate, because the relationship is created at the moment the powder is reconstituted. This calculator performs that translation. Enter the milligram total on the vial and the millilitres of diluent added, and it derives the concentration in mg/mL, then converts any milligram figure you type into the corresponding volume and syringe-unit reading.

It also answers two questions that follow from the same arithmetic: how many equal portions of a given size a vial theoretically contains, and how much material and liquid remain once a chosen number of those portions has been withdrawn. Each result is displayed beside the calculation that produced it, so you can reproduce every figure independently with a pen.

The scope stops there. This is a units-conversion tool with no dosing table, no titration ladder and no knowledge of any individual. Tirzepatide is a prescription medicine, and how much of it a person should use — or whether they should use it at all — is a decision for a licensed prescriber working from an approved product label, not for a web page.

How to use the calculator

Vial amount (mg). The total milligrams in the vial, read from the label. Lyophilised tirzepatide is commonly encountered in 5, 10, 15, 20, 30 and 60 mg vial totals. Enter the whole vial figure here, not the amount you intend to measure out.
Reconstitution volume (mL). The diluent volume you actually added, usually bacteriostatic water. This single number determines the concentration, and therefore every volume and unit figure the calculator returns.
Amount to measure (mg). The milligram figure you want expressed as a volume. Tirzepatide amounts are usually stated in whole or half milligrams — enter 2.5, not 2500 micrograms.
Syringe size (mL). The capacity of the barrel: 0.3 mL, 0.5 mL or 1 mL. If the volume required will not fit in one draw, the calculator says so instead of quietly returning an unusable number.
Syringe unit scale. Choose the scale printed on your syringe: U-100, U-50 or U-40. The unit conversion changes with this selection, because a "unit" is only defined relative to that scale.
Portions already drawn. Optional. Enter how many equal portions have been removed to see what remains in the vial, in both mg and mL.

Results recompute as you type. Copy results puts the full calculation, inputs included, on your clipboard, and Reset restores the starting values. Invalid entries — blank fields, zero or negative numbers, an amount larger than the vial holds — produce a specific message rather than a silent wrong answer.

What tirzepatide concentration means

Concentration expresses how much peptide occupies each millilitre of solution, written as mg/mL. Before reconstitution a vial has no concentration at all: 10 mg of dry powder is simply 10 mg of mass sitting in glass. Concentration is something you create by choosing a diluent volume, and the choice is arbitrary in the arithmetic sense — the same vial can legitimately become 10 mg/mL, 5 mg/mL or 2 mg/mL depending on whether you add 1 mL, 2 mL or 5 mL of water.

Because tirzepatide vials commonly carry larger milligram totals than most peptides, this choice has a wide practical range. A 30 mg vial in 1 mL is 30 mg/mL, where 2.5 mg occupies barely 0.083 mL — around eight units on a U-100 barrel, a reading squeezed into a few gradations. The same 30 mg in 3 mL gives 10 mg/mL, and 2.5 mg then occupies 0.25 mL, or 25 units, spread across a far larger and more legible span of the scale. Neither is more "correct" mathematically; the second is simply easier to measure accurately.

Approved tirzepatide products are supplied as ready-made solutions at fixed strengths and are not reconstituted by the user. This calculator exists for people working with lyophilised material, and the arithmetic it performs is generic to any mg-in-a-vial preparation.

How mg/mL is calculated

Concentration is a single division:

Concentration (mg/mL) = Vial amount (mg) ÷ Diluent volume (mL)

Converting a milligram figure to a volume is the same relationship rearranged:

Volume (mL) = Amount (mg) ÷ Concentration (mg/mL)

These can be collapsed into volume = (amount mg × diluent mL) ÷ vial mg, but the calculator deliberately keeps the concentration on screen as its own result. That intermediate figure is the fastest sanity check available: if you reconstituted a 10 mg vial in 2 mL and see anything other than 5 mg/mL, an input is wrong before the rest of the calculation even begins.

Why concentration changes when the reconstitution volume changes

Adding water never changes how much tirzepatide exists. A 15 mg vial contains 15 mg whether it is dissolved in 0.5 mL or 5 mL. What changes is how thinly that fixed mass is distributed, and therefore how much liquid you must draw to capture any given fraction of it. Concentration and required volume are inversely related: double the diluent, halve the concentration, double the volume for the same milligrams.

This is why a "volume" or a "unit count" copied from someone else is meaningless without the concentration attached. Two people can both draw 20 units from a 15 mg tirzepatide vial and capture completely different quantities of peptide, purely because one used 1.5 mL of diluent and the other used 3 mL. The number of units on a barrel describes liquid, never mass.

How volume relates to syringe markings

Insulin-style syringes are graduated in units rather than millilitres, and the unit is defined by the scale printed on the barrel. The general conversion is:

Syringe units = Volume (mL) × Units per mL (from the barrel scale)

On a U-100 syringe there are 100 units per mL, so 0.25 mL is 25 units. On a U-40 syringe there are 40 units per mL, so the identical 0.25 mL reads as 10 units. On a U-50 barrel it reads as 12.5. The liquid volume is unchanged in all three cases; only the labelling of the scale differs. This is why the calculator asks you to choose the scale rather than assuming one, and why a unit figure quoted anywhere without its scale should be treated as incomplete information.

Note also that syringe capacity and scale are separate properties. A 0.5 mL barrel marked U-100 runs to 50 units; a 1 mL barrel marked U-100 runs to 100. Larger luer-lock syringes are typically marked in millilitres and tenths of a millilitre with no unit scale at all, in which case the mL figure is the one to read and the unit conversion does not apply.

Worked mathematical examples

The following are hypothetical arithmetic illustrations of the formulas above. They exist to demonstrate unit conversion and carry no clinical meaning — they are not dosing suggestions, recommendations or schedules of any kind.

Example 1 — 10 mg vial, 2 mL diluent

Concentration = 10 mg ÷ 2 mL = 5 mg/mL
Volume for 2.5 mg = 2.5 ÷ 5 = 0.5 mL
U-100 units = 0.5 × 100 = 50 units
U-40 units = 0.5 × 40 = 20 units
Portions of 2.5 mg = 10 ÷ 2.5 = 4
Remaining after 2 portions = 10 − 5 = 5 mg (1 mL)

Example 2 — same vial, 1 mL diluent

Concentration = 10 ÷ 1 = 10 mg/mL
Volume for 2.5 mg = 2.5 ÷ 10 = 0.25 mL = 25 units (U-100)

Identical milligrams, half the liquid, half the reading on the barrel. The only thing that changed was the dilution.

Example 3 — 30 mg vial, 3 mL diluent

Concentration = 30 ÷ 3 = 10 mg/mL
Volume for 5 mg = 5 ÷ 10 = 0.5 mL = 50 units (U-100)
Volume for 7.5 mg = 7.5 ÷ 10 = 0.75 mL — exceeds a 0.5 mL barrel, so it will not fit in one draw
Portions of 5 mg = 30 ÷ 5 = 6

Example 4 — a figure that does not divide evenly

Concentration = 15 mg ÷ 2 mL = 7.5 mg/mL
Volume for 2.5 mg = 2.5 ÷ 7.5 = 0.3333 mL = 33.33 units (U-100)
Portions of 2.5 mg = 15 ÷ 2.5 = 6
Portions of 4 mg = 15 ÷ 4 = 3.75 → 3 whole portions, 3 mg left over

A volume of 0.3333 mL falls between gradations on any barrel. The calculator reports the exact figure and the whole-portion count separately rather than concealing the remainder inside a rounded number; choosing a diluent volume that yields tidier arithmetic is usually easier than trying to read a third of a unit.

mg, mL and syringe units are three different things

Milligram (mg) — a mass. It states how much tirzepatide is present and does not change when diluent is added.
Millilitre (mL) — a volume. It states how much liquid is in the barrel and says nothing about what is dissolved in it.
Syringe unit — a marking on a graduated barrel, defined by that barrel's scale. One unit is 1/100 mL on a U-100 syringe and 1/40 mL on a U-40 syringe. It is a volume label under another name, never a quantity of peptide.
Microgram (mcg) — one thousandth of a milligram. Rarely used for tirzepatide, but if you meet a microgram figure, divide by 1000 before entering it here.

Concentration is the only bridge between mass and volume, and the barrel scale is the only bridge between volume and units. A statement like "20 units is 2 mg" is incomplete unless both the mg/mL concentration and the syringe scale are given alongside it.

Common calculation errors

Assuming every syringe is U-100. U-40 barrels exist and are visually similar. Reading a U-40 syringe as though it were U-100 misstates the volume by a factor of two and a half.
Reusing a unit count after changing the dilution. A figure that was correct for a 10 mg vial in 2 mL is wrong the moment the next vial is reconstituted in 1 mL. Recalculate for every new vial.
Entering the amount you want instead of the vial total. The first field is the whole vial. Putting 2.5 there when the vial holds 10 mg quadruples every downstream figure.
Using the intended diluent volume rather than the added one. If you meant to add 2 mL but the syringe delivered 1.8 mL, the real concentration is higher than planned. Enter what actually went in.
Believing dilution changes the total. More water never creates more peptide. A 15 mg vial holds 15 mg at every concentration.
Rounding too early. Rounding the concentration before dividing compounds the error, which matters most at high concentrations where small volumes are involved. This calculator carries full precision internally and rounds only for display.

Limitations and safety considerations

The arithmetic assumes the diluent volume you enter is the final volume of solution and that the powder dissolves fully and evenly. Neither is exactly true: the dissolved solid contributes a small volume of its own, and a residue of liquid always remains on the vial walls and in the needle hub, so the last portion in a vial is frequently slightly short of the theoretical figure. Vial fill quantities also carry manufacturing tolerance, and material sold as a research chemical is not subject to the identity, purity and content testing applied to a licensed medicine — a milligram figure on such a label is an assumption the calculator inherits, not a measurement it can verify.

Beyond the mathematics, tirzepatide is a prescription-only medicine with a documented adverse-effect profile and specific contraindications and warnings recorded in its approved labelling, and regulators including the FDA have issued public alerts about counterfeit and unapproved tirzepatide products circulating outside the regulated supply chain. Those are clinical and legal questions that no calculator can address. Our medical disclaimer sets out the full scope of what this site does and does not do.

Tirzepatide's clinical and regulatory status

Tirzepatide is a synthetic peptide developed by Eli Lilly that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — the feature that distinguishes it from single-target GLP-1 receptor agonists such as semaglutide. Fatty-acid modification extends its persistence in circulation, giving a half-life of roughly five days and supporting once-weekly administration in its approved products.

It is an approved medicine rather than an investigational one. The FDA and the EMA have authorised tirzepatide products for type 2 diabetes and, subsequently, for chronic weight management, each with its own approved label, indications and prescribing information. The evidence base is peer-reviewed and substantial: the SURPASS programme examined glycaemic outcomes in type 2 diabetes and the SURMOUNT programme examined weight outcomes in obesity, with results published in journals including the New England Journal of Medicine and The Lancet. Gastrointestinal adverse events are the most frequently reported across these trials. This is factual background only and does not indicate that tirzepatide is appropriate for any particular person.

For mechanism of action, half-life, administration route, reported effects, storage and our evidence grading, see the full Tirzepatide profile.

Peptide Reconstitution Calculator — the generic mg, mL and syringe-unit calculator that works for any peptide vial.
Tirzepatide profile — mechanism of action, half-life, administration, side effects, research references and evidence grade.
Tirzepatide vs semaglutide — open the comparison table with tirzepatide preloaded and add semaglutide alongside it.
Tirzepatide vs retatrutide — the same table, comparing the dual agonist against the triple agonist.
Semaglutide calculator — the same maths applied to the sub-milligram figures typical of semaglutide.
Retatrutide calculator — reconstitution and concentration arithmetic for retatrutide vials.
Reconstitution guide — the general mixing, storage and concentration principles behind these calculators.
Peptide database — every profile on the site, searchable by category and evidence grade.

Sources & references

U.S. Food and Drug Administration — Drugs@FDA approved product records and prescribing information for tirzepatide products.
European Medicines Agency — European public assessment reports (EPAR) for tirzepatide-containing medicines.
Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503–515.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
ClinicalTrials.gov — SURPASS and SURMOUNT trial records for tirzepatide.
Eli Lilly and Company — official product and pipeline information for tirzepatide.

Educational and mathematical content only. Nothing on this page is medical advice or a dosing recommendation.

Tirzepatide Calculator